RecruitingPhase 1NCT07184450

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Clinical Study of BCMA/CD70 Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) in the Treatment of Refractory Pediatric Rheumatic Diseases

Sponsor

Chongqing Precision Biotech Co., Ltd

Enrollment

11 participants

Start Date

Sep 1, 2025

Study Type

INTERVENTIONAL

Conditions

Systemic Sclerosis (SSc)Polyarticular Juvenile Idiopathic Arthritis Primary Sjogren's Syndrome Juvenile Dermatomyositis (JDM)

Summary

This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA/CD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.

Eligibility

Min Age: 5 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called BCMA/CD70-targetd CAR-T for people with juvenile dermatomyositis (jdm), polyarticular juvenile idiopathic arthritis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 5 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBCMA/CD70-targetd CAR-T

Subjects underwent lymphocytetion cheotherapy and then received a single intravenous cell infusion

Locations(1)

Children's Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07184450

Related Trials

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT070879122 locations

Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(1)

Related Trials

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Systemic Sclerosis DIet for GastrointESTinal Symptoms

Controlling Hyperactive Immunity With Long-lived Lymphocytes

MTS109 in Patients With Refractory Autoimmune Diseases